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Abstract: 
 
This paper examines whether or not hospital competition in a market with fixed 
reimbursement prices can prompt improvements in clinical quality.  In January 2006, the 
British Government introduced a major extension of their market-based reforms to the 
English National Health Service. From January 2006 onwards, every patient in England 
could choose their hospital for secondary care and hospitals had to compete with each 
other to attract patients to secure their revenue. One of the central aims of this policy was 
to create financial incentives for providers to improve their clinical performance.  This 
paper assesses whether this aim has been achieved and competition led to improvements 
in quality.  For our estimation, we exploit the fact that choice-based reforms will create 
sharper financial incentives for hospitals in markets where choice is geographically 
feasible and that prior to 2006, in the absence of patient choice, hospitals had no direct 
financial incentive to improve performance in order to attract more patients.  We use a 
modified difference-in-difference estimator to analyze whether quality improved more 
quickly in more competitive markets after the government introduced its new wave of 
market-based reforms.  Using AMI mortality as a quality indicator, we find that mortality 
fell more quickly (i.e. quality improved) for patients living in more competitive markets 
after the introduction of hospital competition in January 2006.  Our results suggest that 
hospital competition in markets with fixed prices can lead to improvements in clinical 
quality. 
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1. Introduction 
 
Increasingly, policy-makers across the world are embracing hospital competition in order 
to create financial incentives for health care providers to improve quality and efficiency. 
England has not been an exception to this trend.  Over the last two decades, successive 
governments in England have introduced two waves of market-based reforms, each of 
which was centered on increasing hospital competition in the state-funded National 
Health Service (NHS).  The latest wave of reforms, which came into force in January 
2006, gave every NHS patient a choice of their secondary care provider and allowed 
hospitals to compete with each other to attract patients.  However, in spite of significant 
interest in creating sharper financial incentives in the health care sector, there is not a 
consensus on how health care markets should be structured or on the impact of hospital 
competition on clinical quality (Dranove and Satterthwaite, 1992, Dranove and 
Satterthwaite, 2000, Gaynor, 2004, Gaynor and Haas-Wilson, 1999).  This ambiguity 
about the theoretical impact of competition on clinical quality together with ideological 
opposition to introducing competition into the NHS has made the most recent wave of 
English NHS reforms, commonly referred to as the ‘patient choice’ reforms, remarkably 
controversial (Dixon, 2009). 
 
The crucial difference between the first wave of NHS reforms in the mid-1990s and the 
post-2006 patient choice reforms was the extent to which hospitals could compete on 
both price and quality.  During the 1990s NHS internal market, hospitals could set their 
own prices and they competed for annual contracts on the basis of their price and quality.  
A decade later, in the most recent way of market-based reforms, prices were set centrally 
by the UK Department of Health and hospitals could only compete for market-share on 
the basis of their quality.  Gaynor (2004) has hypothesized that hospital competition in 
markets with fixed reimbursement prices may improve clinical quality, whereas hospital 
competition in markets where firms can set their own prices may reduce clinical quality.  
Consistent with this hypothesis, Propper et al. (2004) and Propper et al. (2008) found that 
higher hospital competition in the 1990s NHS internal market, when reimbursement 
prices were variable, was associated with an increase in hospital mortality. 
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 This paper examines whether hospital competition during the latest wave of NHS reforms 
led to improvements in clinical quality.  We hypothesize that as hospitals were exposed 
to financial incentives to compete for patients on published quality measures like 
standardized hospital mortality, surgical volume and infection rates in a market with 
fixed prices, hospitals likely took steps to improve their clinical performance.  We use the 
January 2006 formal introduction of hospital competition across England to create a 
quasi-natural experiment to estimate the impact of hospital competition on clinical 
quality, which we measure using 30-day in hospital mortality from acute myocardial 
infarction (AMI).  For our estimation, we exploit the fact that choice-based reforms will 
create sharper financial incentives for hospitals in markets where choice is geographically 
feasible and that prior to 2006, in the absence of patient choice, hospitals had no direct 
financial incentive to improve performance in order to attract more patients. Specifically, 
we use a modified difference-in-difference (DiD) estimator to test whether patient 
outcomes in high-choice areas have improved at a significantly faster rate post-reform 
than in low-choice areas after all patients in England were formally given the ability to 
select their hospital in January 2006. 
 
Ultimately, we find that after the formal introduction of patient choice in January, AMI 
mortality decreased more quickly for patients living in areas with more competitive 
spatial hospital markets.  In the three-year period after the reforms were introduced in 
2006, one standard deviation more hospital competition was associated with 
approximately a 1% decrease in AMI mortality.  In short, higher hospital competition 
was associated with faster rate of decrease in AMI mortality.  There is significant 
evidence in England that in-hospital time to thrombolysis and the availability of 
angioplasty vary significantly across NHS hospitals (Walker et al., 2009).  Given that 
both factors are strongly associated with AMI mortality, one explanation for our results is 
that increased competition led to faster uptake of angioplasty and/or an increase in the 
speed at which patients receive thrombolysis, although our data do not allow us to 
ascertain whether or not that was the case (Fibrinolytic Therapy Trialists' (FTT) 
Collaborative Group, 1994, Gale et al., 2008, GUSTO investigators, 1993, Zijlstra et al., 
2 
 
1999).  Our results support the hypothesis that in markets with fixed prices, hospital 
competition can improve patient outcomes. 
 
Our work makes additional contributions to the empirical literature on spatial hospital 
competition by carefully addressing the potential endogeneity of spatial competition 
measures to hospital quality.  In this respect, to bolster our DiD strategy we: a) base 
market structure on patients' residential location rather than hospital location; b) measure 
competition from patient choices over elective procedures, but measure health service 
quality using an emergency procedure (AMI) that is a marker for overall clinical quality; 
c) devise an instrumental variable (IV) strategy that exploits the variance in distances 
between where people live and their four nearest hospitals as a source of exogenous 
variation in hospital market power; and d) present various tests that indicate that our 
estimates arise, post-reform, from market structure in the health service, and not from 
spurious aspects of urban-density. 
 
This paper is structured as follows.  Section 2 outlines the recent NHS market-based 
reforms and contrasts them to the internal market reforms of the 1990s.  Section 3 
examines the existing literature on the impact of hospital competition on quality.  Section 
4 presents our data, outlines our various measures of competition and our empirical 
model.  Section 5 contains our results.  Section 6 includes an analysis of our results and 
our conclusions. 
 
2. Competition in the English NHS 
 
The pre-1990 English National Health Service (NHS) was driven by central government 
control and had few financial incentives for quality or efficiency (Cutler, 2002).  In the 
four decades after the NHS was founded, successive governments were able to control 
costs using supply-side regulation and prospective hospital budgeting.  The high degree 
of centralization allowed spending in the UK to grow more slowly than spending in 
almost every other developed country (Cutler, 2002).  On the other hand, the heavy 
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centralization in the UK likely gave rise to inefficiency and delayed the uptake of new 
technology (McClellan et al., 1999). 
 
The most notable feature of the internal market was that it separated the providers of 
health care from the purchasers of health care (Propper et al., 2004).  Newly formed local 
bodies would consider the needs of their patient population and establish annual contracts 
to purchase a fixed number of surgical interventions from local hospitals (Le Grand et al., 
1998).  The hope was these new purchasers would purchase wisely and maximize quality 
for the lowest price, since both the price and quality of the services being purchased was 
variable.  The internal market remained in operation until 1997, when the newly elected 
Labour party dismantled most elements of it, but retained the separation between 
purchasers and providers. 
 
Traditional microeconomic theory predicts that competition will lead to more efficient 
welfare outcomes.  However, there is a growing literature noting the potential for price 
and quality competition to have a deleterious impact on quality in health care markets, if 
hospitals have the freedom to set both the price and the quality of service delivery 
(Chalkley and Malcomson, 1998, Gaynor, 2004).  Ultimately, the outcome of 
simultaneous price and quality competition is dependent on whether or not purchasers are 
equally sensitive to both price and quality (Gaynor and Haas-Wilson, 1999, Propper et 
al., 2004, Propper et al., 2006).  In competitive health care markets, where quality is 
noisy and often difficult to measure, purchasers may well be significantly elastic to price 
and as a result, quality may suffer (Chalkley and Malcomson, 1998, Gaynor, 2004, 
Kranton, 2003, Volpp et al., 2003).  Conversely, Gaynor (2004) draws on a well 
established body of literature to show that in fixed price competitive hospital markets, as 
long as the reimbursement rate per procedure is greater than the hospitals’ marginal costs 
per episode of care, the quality of care provision should rise (Gaynor, 2004). 
 
The most recent wave of market-based reforms to the NHS had four key elements, all 
implemented between 2003 and 2008, which created financial incentives for hospitals to 
attract patients and introduced hospital competition.  Figure 1 is a timeline of the key 
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elements of the reforms.  Prior to 2006, the government introduced several policy 
elements necessary to support hospital competition and on January 1, 2006, the incentives 
from hospital competition came into force.   We regard January 1, 2006 as our ‘policy on’ 
date, and the first point when hospitals were significantly exposed to financial incentives 
from competition. 
 
In an effort to create an environment that would support competition, beginning in 2002, 
the health service increasingly began paying for NHS patients to receive care in private 
sector facilities and attempted to increase and diversify the hospital sector in England 
(Department of Health, 2002).  The NHS helped coordinate and fund the development of 
Independent Sector Treatment Centers (ISTCs) which were to provide elective surgery 
and diagnostic services.  Between 2002 and 2008, 42 ISTCs opened across England and 
they are projected to eventually provide up to 15% of elective care (Propper et al., 2006).  
The government encouraged private sector hospitals to enter the market so that patients 
would have additional choice for elective care and NHS hospitals would face increased 
competition to attract patients.  At the same time, in an effort to encourage local 
innovation, the government gave high performing hospitals additional fiscal, clinical and 
managerial autonomy.  Hospitals that earned additional autonomy were referred to as 
‘foundation trusts’. 
 
In 2005, the government implemented a new fixed-price funding mechanism called 
‘Payment By Results’ (PBR), which was largely a case-based payment system modeled 
on the diagnosis-related group (DRG) payment system in the US (Department of Health, 
2009a). Previously, hospitals were paid via annual budgets and bulk-purchasing contracts 
from local purchasing organizations with little attention to clinical quality (Chalkley and 
Malcomson, 1998).  The key feature of the PBR system in relation to the market-based 
reforms was that the money in the health system would eventually follow the patients’ 
choices so that hospitals were only paid if they were able to attract patients (Le Grand, 
2007, Dixon, 2004).  The Department of Health created service-related tariffs and 
adjusted them according to several factors such as whether a hospital was an academic 
center, patient severity and local wage rates (Department of Health, 2009a). 
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 After diversifying the hospital sector, adding additional capacity to the health system and 
introducing a reimbursement scheme that rewarded hospitals for attracting patients, the 
government was in a position to tie hospitals’ financial success with their ability to attract 
patients.  From January 2006 onwards, the major plank of the government’s market 
reforms came into force and patients were given the ability to choose between four or 
more providers for secondary care (Department of Health, 2002, Department of Health, 
2003, Department of Health, 2004, Department of Health, 2009b).1  By giving patients 
the ability to choose their hospital and allowing money to follow patients through the 
health system, hospitals had financial incentives to attract patients.  In April 2008, 
patients were given the ability to choose from any provider in England, as long as the 
provider met NHS standards, and were paid using the traditional NHS tariff (Department 
of Health, 2007, Department of Health, 2009b). 
  
Along with giving patients a formal choice of where they could receive secondary care, 
the government also introduced a new information system that enabled paperless referrals 
and appointment bookings and provided information on quality to help patients make 
more informed choices (Department of Health, 2009a).   The paperless referral and 
appointment system, known as ‘Choose and Book’, allowed patients to book hospital 
appointments online, with their general practitioner (GP) or, if they preferred, by 
telephone (Department of Health, 2009d).  The booking interface gave the person 
booking the appointment the ability to search for hospitals based on geographic distance 
and see estimates of each hospitals’ waiting times that were based on the last 20 
appointments at each hospital.  The ‘Choose and Book’ system was rolled out as patients 
in the NHS were given a choice of their secondary care provider. 
 
In 2007, the government also created a website designed to provide additional quality 
information to inform patients’ choices.  The hope was that providing additional quality 
                                                 
1 From 2003 – 2005, certain patients living in London and Manchester who were waiting 
for long periods of time were allowed to choose receive care at an alternative that had a 
shorter waiting time .   
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information to inform patients’ choice would create an environment where hospitals 
competed on quality, not price.  The website currently includes information collected by 
the national hospital accreditation bodies, including risk-adjusted mortality rates, and 
detailed information on waiting times, infection rates and hospital activity rates for 
particular procedures (Department of Health, 2009c).  The website also includes patient 
comments and more detailed information on hospital accessibility, general visiting hours 
and parking arrangements. 
 
In the previous internal market, with price and quality competition, hospitals faced a 
downward sloping demand curve.  Crucially, hospitals faced a tradeoff between price, 
quality and volume.  Higher fees might have meant that hospitals could generate more 
revenue per patient, but higher prices might have also led to lower demand for their 
services.  In the current market in the NHS, hospitals have to maximize the difference 
between their revenues and costs with no consideration of the impact price will make on 
the volume of care they deliver because prices are fixed.  In contrast with the internal 
market, purchasing decisions during this latter wave of market-based reforms could not 
be driven by the price of services.  Instead, hospitals can only differentiate themselves 
based on their location, and on their real and perceived quality. 
 
We hypothesize that the incentives for clinical quality created in the second wave of 
market-based reforms are sharper than the incentives for quality created during the 
internal market period.  There may be particularly significant incentives for quality 
during the second wave of reforms because in the NHS, a key component of a GP’s role 
is to serve explicitly as an agent choosing secondary care for their patients. Elsewhere, 
Allen (1984), Klein and Leffler (1981) and Shapiro (1983) have found that even in 
markets with imperfect information, there is likely to be an equilibrium with optimal 
quality if consumers can perceive quality ex post and providers have an interest in 
attracting repeat business.  Since GPs serve as agents for different patients for the same 
set of conditions on an ongoing basis, they are well positioned to observe quality ex post 
and use that information to advise future patients. In effect, despite the fact that patients 
seldom attend hospitals for the same procedures twice, the fact that GPs are often 
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involved in the same referral decisions countless times means that they are able to 
significantly inform patient choices through information on ex post quality.  As a result, 
we expect that after 2005, clinical quality should rise in more competitive hospital 
markets in England, unlike the positive relationship between competition and mortality 
that Propper et al. (2004) and Propper et al. (2008) observed during the initial internal 
market reforms. The dominant focus of the paper is testing this hypothesis. 
 
One important point before we proceed.  In both the internal market and the current wave 
of market-based reforms in England, the state is still responsible for funding health care.  
In both incarnations, the markets that were created can be characterized as ‘quasi-
markets’ (Le Grand and Bartlett, 1993).  The general idea behind ‘quasi-markets’ is that 
the state no longer combines the funding and provision of services, but rather confines its 
role to paying for and purchasing care from a variety of providers.  On the demand side, 
there may be decentralized purchasing, but in most cases, most of the funds start from 
central government.  On the supply side, there is competition between providers, which 
may themselves be state-run, private, or non-profit.  In the current wave of reforms, 
private hospitals distribute their profits to shareholders and traditional NHS facilities 
which dominate the market re-invest their profits and may distribute them in the form of 
higher pay for staff and management. 
 
3. Evidence on The Relationship Between Hospital Competition and Clinical Quality 
 
The bulk of the literature assessing the relationship between hospital competition and 
quality comes from the US (Dranove and White, 1994, Kessler and McClellan, 2000, 
Propper et al., 2006).  At present, there is very little evidence on the impact of 
competition on quality in the UK and almost no empirical evidence on the impact of the 
latest wave of market-based NHS reforms on clinical quality. Given the emphasis we 
place on differentiating between the incentives in fixed price and variable price hospital 
markets, we discuss whether the studies below occurred in fixed price or variable price 
settings. 
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3.1 US evidence on the impact of hospital competition on clinical quality 
 
Historically, the bulk of the existing competition literature from the US investigates the 
relationship between competition, prices and capacity (Dranove and Satterthwaite, 1992, 
Hughes and Luft, 1991, Joskow, 1980, Noether, 1988, Robinson and Luft, 1985a, 
Robinson et al., 1987, Robinson and Luft, 1985b, Wolley, 1989, Zwanziger and Melnick, 
1988, Gruber, 1994).  However, there is a growing literature in the US that looks at the 
impact of hospital competition on clinical performance (Gowrisankaran and Town, 2003, 
Ho and Hamilton, 2000, Kessler and Geppert, 2005, Kessler and McClellan, 2000, 
Mukamel et al., 2002, Propper et al., 2004, Sari, 2002).  The trend emerging from the 
more recent work on competition and quality is that under fixed-priced competition, 
higher levels of competition generally lead to improvements in clinical performance, so 
long as the reimbursement price covers the marginal cost (Gaynor, 2004). 
 
Kessler and McClellan (2000) examined the impact of hospital competition on AMI 
mortality for Medicare beneficiaries from 1985 to 1994 in a market with fixed prices.  
They simulate demand in order to create measures of competition that are not based on 
actual patient flows. They find that in the 1980s, the impact of competition was 
ambiguous, but in the 1990s, they find that higher competition led to lower prices and 
lower mortality.  Using similar methodology, Kessler and Geppert (2005) found that 
competition was not only associated with improved outcomes in their Medicare 
population, but it also led to more intensive treatment for sicker patients, and less intense 
treatment for healthier patients who needed less care.  Gowriskaran and Town (2003) also 
simulate demand in order to measure competition and examine the impact of competition 
in a fixed price Medicare market and in a variable priced market for HMO patients.  They 
find that in the fixed price market, higher competition led to an increase in mortality 
(Gowrisankaran and Town, 2003).  However, they hypothesize that their results stem 
from the fact that hospitals in California were underpaid for Medicare patients with AMI, 
rather than from competition.  This is consistent with research, which found that lower 
Medicare reimbursement rates led to increases in mortality, particularly in competitive 
markets (Shen, 2003). 
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 In a variable price setting, Gowriskaran and Town (2003) found that higher competition 
led to lower mortality.   Likewise, Sari (2002) found that higher hospital concentration in 
a variable priced market led to a significant reduction in clinical quality.  Whereas most 
research relies on 30-day AMI mortality as the dominant measure of quality, Sari 
measured quality via obstetric complications, iatrogenic complications, wound infections 
and the provision of inappropriate services. Hamilton and Ho (1998) looked at 
competition by examining hospital mergers and found that there was no significant 
relationship between competition and mortality. Volpp et al. (2003) exploit the fact that 
from 1991 through 1996, New Jersey introduced price competition and smaller subsidies 
for the uninsured, whereas New York State did not. Using a DiD framework, Volpp et al. 
(2003) found that price deregulation and a decrease in subsidies for the uninsured was 
associated with a significant increase in AMI mortality. 
 
3.2 English evidence on the impact of hospital competition in the NHS 
 
Nearly all of the English literature on hospital competition is based on the initial NHS 
internal market reforms.  To our knowledge, there has been no evidence published thus 
far on the impact of hospital competition on clinical quality during the newly created 
market. 
 
In general, there is a near uniform consensus that the internal market never created sharp 
incentives for hospitals or a significant degree of competition (Klein, 1999, Le Grand, 
1999, Le Grand et al., 1998).  There is some evidence that prices fell during the internal 
market (Propper, 1996, Propper et al., 1998, Soderlund et al., 1997); however, Soderlund 
et al (1997) found that higher competition was not associated with lower quality. 
 
Hamilton and Bramley-Harker (1999) examined the impact of the NHS internal market 
on patient waiting times and length of stay for hip replacement from 1991 through 
1994/5.  Using survival analysis to look at hospital level data during the internal market 
reform period, they found that waiting times for hip replacements fell and so too did 
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patients’ average length of stay (Hamilton and Bramley-Harker, 1999).  In addition, their 
results suggest that after the internal market was introduced, patients were more likely to 
be transferred to another facility, rather than remaining in the hospital where they had the 
surgery until they were ready to be discharged home. 
 
The strongest evidence on the impact of hospital competition on patient quality in the 
NHS comes from Propper et al (2004) and Propper et al. (2008), which considers this 
impact under a variable price market regime.  Propper et al. (2004) measure competition 
using hospital counts within markets defined using a 30-minute drive time from ward 
centers.  Using hospital level data and controlling for hospital and local area 
characteristics, they find that higher competition led to a statistically significant increase 
in 30-day AMI mortality that was larger than the mortality decline attributed to 
technological innovation during the same period (Propper et al., 2004).  Propper et al 
(2004) estimate that a shift from the 25th to the 75th decile in the competition distribution 
resulted in a 0.01 reduction in the mortality rate, which was approximately 20% of the 
standard error.  A further 2008 study by Propper et al. uses hospital panel data and a DiD 
estimation over a longer time period to see whether more competitive areas had higher or 
lower AMI mortality.  Similar to their findings from previous work, Propper et al. (2008) 
found that higher competition during periods of competition was associated with higher 
AMI mortality. 
 
3.3 Empirical Challenges Measuring Competition 
 
One of the major challenges for researchers analyzing the impact of hospital competition 
on clinical quality is developing accurate measures of hospital spatial competition (Baker, 
2001).   There are two important issues in this respect: first, how to define the appropriate 
market area; and second what index of competition to use to quantify competition within 
the defined market. 
 
There is general agreement that administrative boundaries make for poor definitions of 
hospital markets (unless patients are constrained to providers within those boundaries). In 
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order to create more accurate market definitions, investigators typically calculate market 
size in one of three ways.  One option is to create a fixed radius, defined by a largely 
arbitrary distance that creates a circular market of radius r.  Investigators then calculate 
the degree of competition inside that circular market.  A second option is to create a 
variable radius market where the radius r that dictates the size of the market varies 
according to pre-existing referral patterns, actual patient flows, or hospital catchment 
areas.  For instance, a variable radius r could be set at a length that captures the home 
addresses of 75% of patients that attended a particular hospital. A third option is create a 
radius that varies according to travel distance.  An example of a travel-based radius 
would be to define radius r as the distance that captures the hospitals within a thirty-
minute travel time from a particular patient’s home address. 
 
Each market definition has its respective strengths and weaknesses.  Fixed radius 
measures may over- or under-estimate the actual size of the market, and in ways that are 
correlated with urban density.  These shortcomings of fixed-radius based measures stem 
from the fact that they do not factor in the typical preferences and travel patterns of 
patients when they estimate the size of the market. For example, a 30km radius 
encompasses nearly all of a major metropolitan area like London, but London-based 
patients are unlikely, in practice, to consider every hospital in London in their choice set. 
Conversely, a rural resident may have only one hospital within 30km but be quite 
prepared to consider other choices further a-field for a one-off elective hospital 
procedure. As a result, the fixed radius measures may suffer from an urban bias in which 
effects caused by differences in (unobserved) characteristics of urban patients, labor 
markets for health professionals and other aspects of urban health provision are falsely 
attributed to hospital competition. Conversely, the advantage of this type of fixed radius 
market definition is that the market size is not dependent on unobserved dimensions of 
hospital quality. 
  
Variable radius measures infer market areas from de-facto patient travel patterns, which 
take into account the actual travel behavior of rural versus urban residents. However, this 
strength is also a drawback in that the market areas revealed by the data may be in part 
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determined by the quality and popularity of hospitals and as a result, be endogenous to 
quality (Kessler and McClellan, 2000).  For example, a relatively high performing 
hospital may have a larger catchment area encompassing more competitors than does a 
lower quality competitor.  It is therefore possible to mistakenly infer a causal link 
between competition and quality, when the correlation is caused by differences in 
hospital quality affecting catchment area size. 
 
Rather than using actual patient flows, Kessler and McClellan (2000) predict flows from 
patient demographics and patient-hospital distances and use the predicted flows to 
calculate competition.  While this measure of competition has clear strengths, the 
drawback of their work is that the measure of competition is only as good as their 
underlying model of patient flows. The idea that patient demographics are exogenous to 
patient health outcomes is also debatable. 
 
Propper et al. (2004) use travel time limits along road networks to define market size, 
based on the assumption that it is road travel time rather than straight-line distance that is 
relevant.  They argue that this definition of market size ameliorates some of the concerns 
raised by Kessler and McClellan (2000).  They rightly suggest that markets defined by 
road travel time limits are, like fixed distance markets, not determined by hospital 
quality.  The authors also suggest that this method improves on fixed distances because 
30-minute time limit zones will be smaller in congested urban locations than in rural 
locations due to lower travel speeds. In practice, however, we will see below that markets 
defined using radii derived from travel distances tend to be highly correlated with fixed 
radius markets, so the advantages of time over distance may be hypothetical. 
 
Once investigators determine the size of hospital markets, the next challenge is selecting 
an appropriate index of competition. According to the industrial organization literature, a 
standard measure of competition is the Hirschman-Herfindahl index of market 
concentration. However, this index was designed for use in aggregate analyses, in which 
the market-specific HHI applies to the market as a whole and to every firm or service 
provider within that market and not to estimate competition for single firms.  When HHIs 
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are calculated for individual firms, they are subject to extensive bias because the 
observed concentration is often the result of each firm’s quality.  For example, a highly 
rated hospital that attracts patients away from its neighbors will appear to operate in a 
concentrated market because the concentration is an outcome of its quality.  An 
alternative strategy is simply to consider one component of the HHI - the number of 
competitors in the market. This solution is the one adopted by Propper et al. (2004) and 
Propper et al. (2008).  The disadvantage with this strategy is that it disregards inequality 
in the shares in the marker, which may be an important indicator of competitive forces 
and the underlying market dynamics. 
 
On balance, therefore, there are no perfect measures of market size or competition.  Each 
measure has respective strengths and weaknesses.  In our empirical work we will use 
variable radius market areas, which we argue are better in principle than fixed distance-
based or time-based markets at eliminating urban biases. However, we take a number of 
steps to overcome the potential endogeneity of indices based on patient flows. These are 
described in detail in our methods section below. We also show that our results are 
similar using four different types of market definitions: a fixed radius measure, two 
variable radius-based measures and a variable time travel measure. 
 
4. Data Sources, Measures of Competition, and Estimation Methods 
 
4.1 Data sources and setup 
 
Our paper relies on patient-level data from 2002 through 2008 that are derived from the 
NHS Wide Clearing Service.  The data are drawn from a large administrative dataset, 
which records nearly every inpatient spell in the NHS and provides a wide range of 
information on patients and their treatment. Each observation in this dataset is a separate 
hospital admission.  Our analysis also makes use of data on admissions for elective 
procedures (hip replacement, knee replacement, knee arthroscopy, cataract repair and 
hernia) in the construction of competition variables. 
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 Our indicator of health service quality is whether or not a patient admitted for an acute 
myocardial infarction (AMI) died within the hospital within 30 days of admission.  Risk-
adjusted 30-day AMI mortality is a commonly used measure of clinical performance that 
is frequently used in the literature assessing the relationship between competition and 
quality, for example in Volpp et al. (2003), Propper et al. (2004) and Propper et al. 
(2008).  In our analysis, we include every patient who had a main International 
Classification of Disease (ICD) 10 code of I21 or I22 and only include emergency AMI 
admissions and admissions where the patients’ length of stay was three days or more 
(unless the patient died within the first three days of being admitted) (World Health 
Organization, 2009).2  
 
There is a large literature on the role, usefulness and drawbacks of hospital mortality as a 
measure of clinical quality (Thomas and Hofer, 1998, McClellan and Staiger, 1999).  
While 30-day AMI mortality is a frequently used measure of clinical quality, there are 
several issues with its use.  First, as with all quality measures, there is a question of 
whether or not a single measure can capture the multidimensional nature of health care 
quality (McClellan and Staiger, 1999).  However, to that end, numerous studies have 
found that risk-adjusted 30-day mortality for AMI is highly correlated with other aspects 
of hospital quality and various process measures of quality (Allison et al., 2000, Chen et 
al., 1999, Dubois et al., 1987, Meehan et al., 1996).  Likely, this is because the same 
elements that lead to high quality AMI treatment are common for treatments for other 
conditions, such as care coordination, the speed of treatment and timely access to surgical 
interventions.  In the context of this paper, mortality from AMI is meant to serve as the 
quality ‘canary in the mineshaft’ for general aspects of clinical performance. 
 
A second issue with 30-day mortality is the noise inherent with this type of measure.  
Because hospitals treat relatively few AMI patients per year, hospital level mortality may 
                                                 
2 We choose to ignore patients with a length of stay of less than three days in order to 
avoid possible up-coding, whereby patients with other conditions were coded as having 
an AMI in order to generate larger reimbursements. 
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vary significantly between years, depending on the patient population a hospital attracts 
in a given year.   This problem is particularly acute when using hospital level data, like 
Propper et al. (2008), where it is difficult to suitably risk adjust and where the analysis 
focuses on average, annual hospital-level performance.  To help attenuate this problem in 
our research, consistent with NHS data cleaning rules, we limit observations to patients 
who were treated at hospitals that saw, at a minimum, 25 AMI patients per year (National 
Health Service Choices, 2009).  Further, because we were using patient-level data with 
risk-adjustments for patients’ age, socio-economic status and co-morbidities and were not 
looking at aggregate level hospital performance, we believe our use of 30-day mortality is 
less subject to bias than research looking at performance at a hospital level. 
 
Elsewhere, McClellan and Staiger (1999) have reported that while 7-day and 30-day are 
highly correlated, 30-day AMI mortality has higher statistical variation than 7-day 
mortality.  As Propper et al. (2008) note, this is seemingly because hospital performance 
has the most direct effect on outcomes during the first 7 days of clinical care.  
Nevertheless, the English government still uses 30-day in hospital mortality as one of 
their preferred measures of quality, rather than 7-day mortality.  Their use of 30-day 
mortality as a quality indicator is consistent with published work from the OECD which 
recommends use of 30-day AMI mortality as one of its key indicators of clinical 
performance (Mattke et al., 2006). 
 
Our patient level data allow us to effectively risk-adjust for clinical severity by 
controlling for patient characteristics in our estimates. These patient characteristics 
include gender, ethnicity, age and Charlson comorbidity score (Charlson et al., 1978). 
The data suppliers use the patients’ home address to link to residential area characteristics 
like urban density and socio-economic status. Socio-economic status is measured at the 
2001 GB Census Output Area Level using the income vector of the 2004 Index of 
Multiple Deprivation (Communities and Local Government Department, 2009). For 
confidentiality reasons, the patient home addresses are not available for use in our 
analysis. However, we do have access to codes that identify the patient's GP and GP 
postcode. There are around 7600-7700 GP postcodes in each year in our data. Patients 
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can usually (at the time relevant for our study) only register at a GP practice if they live 
in the catchment area of that GP. 
 
At the hospital level, we know hospital site postcodes, the NHS Trust to which the site 
belongs and we have indicators of the hospital type (teaching hospitals, Foundation trust 
status) and hospital size.3 Most existing research on the NHS is at the hospital Trust level 
and typically uses the address of the Trust headquarters to define the location where 
patients received care.  This is a very approximate basis for locating hospitals and 
constructing spatial competition variables.  In practice, NHS trusts are usually composed 
of multiple smaller sites, which are sometimes separated by distances of up to 50km, and 
Trust headquarters are often not located where the Trust actually performs clinical care. 
Trust-based competition indices thus miss out on important dimensions of inter-site 
competition both between and within Trusts. 
 
We are able to improve on this by using postcodes of the hospital site where the patient 
receives their treatment. Site postcodes are missing in our data for up to 15% of the 
patient observations, but most of these cases with missing site codes come from patients 
treated at trusts that only actually had one site.  For observations where the site postcode 
was missing and the Trust only had one site, we replace the missing site postcode with 
the Trust postcode.  For the fewer than 2% of observations where there was a missing site 
postcode for a patient treated at a Trust with more than one site, we randomly assigned 
patients to sites within that Trust. 
 
Using geographical coordinates of the GP postcode and hospital site postcode, we 
calculate distances between a patient's GP and the hospital where their secondary care 
was delivered.  This distance is an important component in our analysis and is used as an 
input into our competition measures. For our main analysis, we use matrices of straight-
                                                 
3 Beginning in 2004, high performing NHS Trusts were given ‘Foundation Trust’ status.  
As a result, rather than being than being owned by the NHS, they can be viewed as not 
for profit corporations that are only accountable to their local communities, not the 
central government.  Foundation Trusts have more flexibility than ordinary trusts over 
their management practice, pay scale, and capital investment strategies. 
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line distances. For some of our supplementary results, we calculate origin-destination 
matrices from minimum road travel times along the primary road network. This 
generalized network was provided by the Department of Transport and is populated with 
road link-specific travel speeds derived from their National Transport Model for 2003. 
We generated the GP-hospital origin-destination matrix using the Network Analysis tools 
of ESRI ArcGIS. 
 
4.2 Market Definition and Measures of Competition 
 
As discussed in the literature review, no spatial measure of competition is free from 
problems. Our preferred method of defining market areas is based on a variable radius 
derived from patient flows from GPs to hospitals. Within this market area, to measure the 
degree of market concentration, we calculate the negative natural logarithm of an HHI 
based on hospitals’ patient shares. This negative log transformation of the HHI is 
convenient because it increases with competition, with zero corresponding to monopoly 
and infinity to perfect competition.  For given market area j, our competition index is: 
(1) 
 
nlhhij   ln
nk
N j




2
k1
N . 
 
Here, nk is the number of procedures carried out at hospital site k within market area j 
and Nj is the total number of procedures carried out in market area j. 
 
Both market size and HHI are potentially determined by hospital quality. As a first step to 
mitigate these endogeneity issues, we center market areas on patients’ GPs, not the 
hospital at which they received treatment for AMI. In addition, we base both the market 
radius and the HHIs on the elective procedures carried out by hospitals, not on the share 
of AMIs carried out by hospitals. 
 
 Details of the method of market construction are as follows. Consider an elective 
procedure, e.g. hip replacements, in one year, e.g. 2002. We first use matrices of patient 
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flows from GPs to hospitals for hip replacement in 2002, to deduce GP centered market 
areas. Specifically, we find the radius that represents the 95th percentile of distance 
traveled from a GP to hospitals for hip replacements in 2002. This radius defines the limit 
of the feasible choice set for patients at this GP in 2002. Note, only one patient needs to 
attend a hospital site for that site to modify the GP-centered market radius. We then 
compute the HHI based on all hospitals providing hip replacements within this GP’s 
market area, regardless of whether this GP actually refers patients to all of these 
hospitals. This process is repeated for all GPs, all years 2002-2008 and all five elective 
procedures. A single elective HHI is calculated for each GP and year as a weighted 
average of the procedure-specific HHIs, where the weights are proportional to the volume 
of patients in each procedure category. The final composite elective procedure-based HHI 
thus varies by GP and by year, because both the GP market radius and the distribution of 
patients across hospitals vary by GP and year. We also compute a time-constant GP-
specific market competition variable by averaging across years 2002-2005 for each GP. 
 
This competition index is therefore an indicator of market structure for elective 
procedures in a market zone centered on a patient’s GP. The question we ask in our 
empirical work is whether a GP’s patient receives higher quality clinical care under 
emergency treatment if their GP-centered market for elective care has a more competitive 
structure. By a more competitive structure, we mean more providers and with more 
equally distributed patient shares, which results in a higher negative log HHI. 
 
In the regression analysis presented below, we use a pseudo DiD strategy exploiting the 
NHS choice-policy reforms and IV based methods. We show that other competition 
indices which are potentially less responsive to differences in hospital quality produce 
similar results as estimates using our preferred estimate of competition. The first of these 
alternative indices is derived in an identical way to our 95% variable radius market; 
however the market radius we employ is set to capture the 75th percentile of distance 
traveled from a GP to hospitals each year.  The second of these alternative indices is 
derived in a similar way to the variable radius HHI described above, but using a fixed 
radius from each GP. The third index is an HHI based on travel times along the primary 
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road network from each GP (computed using GIS network analysis tools as described in 
the Data section). Lastly, the fourth alternative strategy we employ is to use the number 
of hospital sites within each market as the measure of market concentration, rather than 
using an HHI. 
 
4.3 Specification of the Empirical Model 
 
In our regression-based empirical analysis, we implement a pseudo DiD estimation 
strategy to estimate the effect of market structure on time trends in the quality of health 
care. This pseudo DiD is based around interaction of a continuous treatment intensity 
variable (the concentration index) with the introduction of choice-based reforms in the 
NHS. 
 
DiD methods are widely used to capture the impact of a policy reform in a non-
experimental setting (Card, 1990, Card and Krueger, 1994, Angrist and Pischke, 2009).  
Traditional DiD regression compares two groups over two time periods where one 
treatment group is exposed to a policy-change in the second period and the second 
control group is not exposed to the policy in either period. Unfortunately, the NHS 
market based reforms that we are investigating do not fit neatly within the traditional DiD 
framework. 
 
First, every area in England was exposed to the reforms so, in principle, there are no clear 
treatment and control groups. In practice, however, the NHS patient choice reforms will 
have had varying impact intensity across the country, where this intensity varies 
according to the amount of choice that is feasible given the geographical configuration of 
homes, GPs and hospital sites.  In some places, market structure permits choice e.g. 
where there are several accessible neighboring hospitals, with similar capacity, offering 
the same procedures. Here, allowing patients to choose where to go for elective surgery is 
expected to make a big difference to inter-hospital competition, assuming hospitals have 
incentives to attract patients. In other areas in England, hospitals operated in de facto 
monopoly markets. For example, there will be less choice when there is only one hospital 
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within a reasonable travel distance, or where there are many hospitals but other 
constraints (e.g. waiting times induced by demand from other patients) take most out of 
the choice set. We assume that the choice reforms will have less 'bite' when market 
structure precludes feasible choice for patients.  Our DiD identification strategy is 
therefore based on the idea that treatment is more intense in the period after the NHS 
choice reforms in places where the local market structure is more competitive. Similar 
ideas have been used in other contexts, for example evaluation of the employment effects 
of the minimum wage (Card, 1992).  The same idea is used in Propper et al. (2008) to 
study the 1990s internal market NHS reforms. 
 
The second modification to the standard DiD set up is that we look for a deviation in the 
time trends in AMI mortality, when we compare high and low competition areas, pre and 
post policy, rather than using the traditional pre/post DiD approach. We adopt this 
strategy partly because the policy reform was not a single step change, but instead 
involved several stages rolled out over time.  It is also partly because we expected the 
reforms to take time to bed-in and that the impact of competition would grow over time. 
A second reason for this modified DiD estimation was that there is also evidence that 
there were some early teething problems immediately after the reforms were introduced.  
Early reports were that it took time for GPs to learn how to use the new referral software 
and become accustomed to providing patients with the opportunity to choose a secondary 
care provider (Healthcare Commission, 2008, Rosen et al., 2007).  As such, the 
incentives from the reforms likely became sharper over time. A third impetus for our 
strategy is that the reforms happened during a period when AMI mortality rates were 
falling rapidly over time due to technological changes (e.g. angioplasty and drug 
treatments) and demographic changes (reductions in smoking). We therefore needed to 
control and test for pre-existing differences in mortality trends over time, between high 
and low competition places rather than comparing mortality before 2006 with mortality 
after. 
   
Taking into account these issues, our empirical regression model takes the form:  
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(2) 1 2 3 4
5
( 2006 | 2006) ( 2006 | 2006)
                +
ijkt jt jt
jt ijkt ijkt
death t t t nlhhi t nlhhi t t
nlhhi controls error
   
 
       
   
Here deathijkt is an indicator (1-0 dummy variable) that patient i, from GP market j, 
treated at hospital site j died within 30 days of admission for AMI in year t. Coefficient 
1 captures the baseline rate of decline in AMI mortality prior to the 2006 reform, for 
locations in which nlhhi=0. These locations correspond to places with only one hospital 
as a feasible choice for patients. Coefficients 1 +2 capture the baseline rate of mortality 
decline in these low-competition places after reform. Now consider a comparator place 
where there is a high degree of choice (e.g. nlhhi=1). The sum 1 +3 is the time trend in 
mortality in these areas before the reform. The sum 1 + 2 + 3 +4 is the time trend in 
mortality in high choice areas after the 2006 reform.  The second partial derivate of the 
death rate trend with respect to differences in competition in the post-policy period is 4. 
This is our coefficient of interest, and is a DiD estimate of the effect of the policy on the 
trends in mortality. This is easily deduced, since: 
 
(3)  Effect of policy on AMI mortality trends = (Trend in mortality in high choice 
places post-policy - Trend in mortality in high-choice places pre-policy) - (Trend 
in mortality in low choice places post-policy - Trend in mortality in low-choice 
places pre-policy) 
 
So, for a given gap in competition nlhhi: 
  
 Effect of policy on AMI mortality trends = ((1+ 2 + 3nlhhi +4nlhhi) – (1 
 +3nlhhi)) – ((1+2) - 1) 
  = 4nlhhi . 
 
The coefficient 3 is also informative, in that it provides the basis for test for the existence 
of pre-policy differences in trends between high and low competition places 30. The 
existence of pre-policy differences in trends would undermine the credibility of the DiD 
strategy. 
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 Note that the specification in (2) includes a vector of control variables as discussed in the 
Data section, and can be generalized to include hospital fixed effects and GP fixed 
effects. Our specifications further include an interaction between Strategic Health 
Authority (SHA) dummies and time trends.4 These interactions control for general 
regional trends and trends associated with SHA policies and changes in regional funding.  
The time trends and SHA year interactions will also pick up the increases in NHS 
funding during this period, since funding for the NHS rose almost uniformly across 
England. 
 
We first estimate (2) using Ordinary Least Squares, and cluster our standard errors at the 
GP level to allow for error correlation across patients within GP markets. Probit or logit 
estimation gives similar results, but the non-linearity of the regression function does not 
make for clean interpretation of 4 as the DiD estimate and it is infeasible to include large 
numbers of fixed effects. 
 
Our estimation sample is restricted to patients who were treated within the market which 
we used to measure competition.  For example, if we define the nlhhi using the 95th 
percentile GP referral share, we restrict our sample to patients who were treated for AMI 
at hospitals within that radius. This eliminates patients who have an AMI and are treated 
at hospitals that are remote from their home, for example if the patient had an AMI at 
work or on vacation. 
 
4.4 Instrumental Variable Estimation 
 
Recall that the two main causes for concern are: a) the nlhhi in equation (2) is potentially 
endogenous to hospital quality in the GP-centered market because of the dependence of 
                                                 
4 There are ten NHS Strategic Health Authorities (SHAs) in England, each representing a 
different region of the country.  SHAs are responsible for implementing the policy that is 
set by the Department of Health and managing local health care provision.  Increasingly, 
policy-making has been devolved to local SHAs.   
23 
 
the market radius and hospital shares on clinical quality; and b) that the coefficients on 
the nlhhi x t interaction in equation (2) may pick up basic urban-rural differences and are 
not specific hospital competition differences. 
 
To address these issues, we provide IV estimates of (2) using an instrument for 
competition based on higher moments of the GP-site distance distribution.  
We instrument for competition using the variation in distances from a patient’s GP to the 
four nearest hospitals as an exogenous source of variation in the GP-centered competition 
indices. We view variation in the GP-to-hospital distances as an exogenous measure of 
completion because if a patient is registered at a GP where there is a high variance in the 
distance to local hospitals, each substitution from one hospital to another will have high 
transportation costs for the patient.  This makes the patient less likely to exercise choice 
and as a result, creates less competitive pressure on local hospitals.   For example, we 
assume patients registered at a GP with its four nearest hospitals located at 1km, 12km, 
27 km and 31km away from the GP will have a stronger pull to their nearest hospital than 
a patient whose GP was located 12km, 15km 17km, and 17km from its four nearest 
hospitals.   The hospital with higher variation in distances will have considerably more 
monopoly power in this particular market, which will and drives down the nlhhi.  Further, 
patients registered at GPs near a location with four hospitals at 13km will have no 
particular travel cost incentives to attend one hospital over another, so the nlhhi increases 
and competitive pressure is greater. 
 
We therefore use the standard deviation in GP-site distance (amongst the nearest four 
sites) as an instrument for nlhhi, conditional on the mean distance to hospitals in equation 
(2). This instrument is interacted with the time trends in the pre and post policy periods to 
provide instruments for the nlhhi x t interactions. The idea is similar to that of predicting 
hospital shares from exogenous variables implemented in Kessler and McClellan (2000). 
However, we implement a more traditional IV, avoiding their non-linear 1st stage 
prediction and predicting from implicit travel costs, not patient demographics (which we 
do not regard as exogenous to patient outcomes). 
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 5. Results 
5.1 Empirical Results 
 
Our estimation sample contains approximately 450,000 patients who had an AMI 
between 2002 and 2008.  There are 227 hospital sites providing care for AMI for patients 
who were registered at 7,742 separate GP practices. As discussed in the methods section, 
our preferred index of hospital market structure is the negative log Hirschman Herfindahl 
Index (nlhhi), centered on General Practitioners, and based on the market within the 
radius to which the GP refers 95% of his/her patients for elective surgery. However, we 
compute the nlhhi based on alternative definitions, some of which are shown in Table 1. 
The indices from fixed radius and time zone based market definitions are very highly 
correlated. Indices based on market definitions using GP hospital flows are quite highly 
correlated with each other, but only moderately correlated with the fixed distance and 
time-based indices. 
 
Figure 2 illustrates why we favor the variable radius methods that infer markets from de-
facto patient choices over hospitals. The first panel shows the competition indices for 
patient referrals for elective procedures derived from 30-minute travel zone markets. The 
dark areas are places with unconcentrated market structure, but the map looks (to anyone 
familiar with England's urban geography) like a map of the major metropolitan areas. 
London is in the South East, Birmingham in the central West, Manchester and Leeds in 
the North. The second panel maps the indices from the 95% GP referral-based markets. 
Now, urban areas are less dominant. Although urbanization is obviously still a factor, 
there is variation in market structure within both urban and rural areas. These maps 
therefore suggest that we stand a better chance of identifying competition effects, rather 
than spurious urban effects, using the GP referral based market definition. 
 
Hospital quality, as measured by thirty-day AMI mortality, improved consistently from 
2002 through 2008, as shown in Table 2.  This reduction in mortality that we observe is 
consistent with international trends and is driven in England in part by increasing 
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adoption of new technology in the treatment of AMI and improvements in public health 
(Walker et al., 2009).  Our aim is to determine whether there is a difference between the 
rate of reduction in AMI mortality in high hospital competition areas in contrast to the 
rate of reduction in low hospital competition areas.  At the same time that mortality was 
decreasing, there was a steady increase in spatial competition in the NHS, also illustrated 
in Table 2.  Consistent with our policy on/off dates, the biggest jump in competition was 
measured after the reforms came into effect in 2006 and patients had the ability to freely 
select a non-local hospital for care. 
 
Table 3 provides our OLS estimates of the DiD specification of equation (2) using our 
preferred index of market structure. This index is the negative natural log of the HHI 
using the 95% GP market defined described in the Methods section.  The regressions 
control for patient characteristics and their underlying health status, hospital 
characteristics, strategic health authority-specific linear time (year) trends, day of the 
week and month the patient received care, plus various combinations of fixed effects as 
described in the Table.  Our main interest is in the coefficient on 2006-2008 trend * nlhhi 
(corresponding to 4 in equation (2)).  The coefficient on that term illustrates the impact 
of the 2006 reforms on the trends in mortality, by comparing markets characterized by 
potentially competitive structures with more concentrated markets. 
 
In each specification in Table 3, we find that after the formal introduction of choice in 
January 2006, mortality decreased more quickly in areas where choice was 
geographically feasible.  The coefficient of our interaction term ranges from -0.0050 to -
0.0068, and is robust to whether or not we include or exclude patient control variables, 
hospital fixed effects or GP fixed effects.  Our estimates are significant in all 
specifications.  Column (5) is our preferred specification and includes both GP and 
hospital fixed effects, which control the possibility of changing GP, patient and hospital 
composition in high competition and low competition areas.5 Based on Column (5), and 
taking a one standard deviation gap in nlhhi as our benchmark (a 0.54), 30 day AMI 
                                                 
5 Appendix 1 includes the fully expanded results from our preferred specifications.   
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mortality fell 0.3 percentage points faster per year after the reform for patients treated in 
more competitive markets. 
 
An essential observation to be made here is that the pre-policy trend in AMI mortality in 
areas with potentially competitive market structures is not statistically different from the 
trend in markets with concentrated structures. The coefficient on the "2002 – 2005 Trend 
* nlhhi" interaction is near zero and statistically insignificant in all specifications other 
than Column 1, which includes no control variables. Conditional on the controls and 
fixed effects, the pre-policy trends in places with concentrated and dispersed market 
structures are identical. This shows that these different markets were balanced in terms of 
the mortality trends pre-reform, and allays fears that the DiD results simply pick up pre-
existing differences in trends. 
 
Table 4 shows that the results are not highly sensitive to the choice of market structure 
index, and presents least squared estimates of (2) using five separate measures.  Column 
(1) of Table 4 repeats our preferred specification and estimates (2) with competition 
measured as the negative log of the Herfindahl index within our variable 95% market.  
Column (2) estimates (2) with competition measured as the negative natural log of the 
HHI within our variable 75% market.  Column (3) estimates (2) with competition 
measured as the negative natural log of the HHI within a fixed 30 km radius around each 
GP.  Column (4) estimates (2) with competition measured as the negative natural log of 
the HHI within a variable radius market that captures the 30-minute travel time around 
each GP.  We limited the observations to patients who received care within the defined 
market.  Our findings remain consistent and significant across the four different measures 
of competition.  The coefficient on the interaction between competition and the 2006-
2008 is always negative and significant, illustrating that higher competition led to lower 
mortality regardless of how we estimate competition. 
 
Column (5) from Table 4 shows the interaction of competition before and after the 
reforms with competition measures as the negative natural log of the HHI with a market 
that captures the distance 95% of patients from each GP practice traveled for care.  
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However, the HHI used in Column (5) is calculated using pre-reform patient flows, and 
averaged across 2002, 2003, 2004 and 2005.  This was a time period when patients did 
not have the ability to choose their provider based on quality.  In essence, this gives an 
estimate of competition that is not potentially sensitive to post-reform changes in quality, 
and not subject to the bias that Kessler and McClellan (2000) discuss.  Using this pre-
reform measure of competition, we also find that higher competition after the 
introduction was associated with a statistically significant reduction in AMI mortality. 
 
Column (6) from Table 4 shows the impact of competition after the reforms were 
introduced, where competition is measured at the hospital level.  Our hospital-based 
index is the average value of our preferred 95% variable GP HHI for the GPs that could 
refer to a particular hospital.  So, if a hospital fell within the market of 6 GPs, the HHI we 
calculated for the hospital was the average of the GPs who had the option of referring 
patients to that hospital.  Like our previous results, we still find that competition after the 
reforms was associated with a faster reduction in AMI mortality.  Interestingly, the 
interaction term associated with this competition measure is significantly larger than the 
measure with our preferred GP-based measure of competition.  One possible explanation 
for this finding is that our GP-based measures are picking up more noise because most of 
the changes that occurred were driven by hospital-level changes in clinical quality. 
 
In addition to using HHIs as measures of competition, we have generated least squared 
estimates of (2) using hospital counts within each market as a measure of competition, 
which are presented in Table 5. While counts are not as sensitive to the underlying 
market characteristics as an HHI, they are more intuitive and serve as a robustness check 
on our HHI estimations. If the hospital shares within markets are equal, then our nlhhi 
index is identical to the log count of hospitals k because the HHI is 1/k. We calculate 
count measures of competition in four types of markets – two variable radius markets, 
one fixed radius market, and one variable time radius market.  Regardless of the count-
based competition measure that we use, we consistently find that the interaction term of 
interest is negative and significant, indicating that a competitive market structure was 
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associated with a statistically significant reduction in AMI mortality after January 1, 
2006. 
 
5.2 Instrumental Variables estimates, robustness and falsification checks 
 
The first column of Table 6 presents our instrumental variables estimates. We instrument 
market structure using the standard deviation of the straight line distance from each GP to 
the nearest four elective providers, controlling for the average distance to all four as 
described in the Methods section. The F-Test on our instruments is significant at p < 
0.001 and the F-statistics are 317.86, 266.29, 218.36, respectively.  The IV estimates 
show a similar pattern to the OLS results in Table 3. The point estimate on our coefficient 
of interest is more than double that in the equivalent OLS specification (Column 3 of 
Table 3), although the standard errors are also higher and the Hausman test indicates no 
statistically significant difference between the IV and OLS coefficient (p=0.08). There is 
no evidence from the IV estimates that it is the endogeneity of market structure to health 
service quality that drives our findings. 
 
Column 2 in Table 7 investigates whether our nlhhi index of market structure simply 
captures non-health specific aspects of dense urban environments. In this specification, 
we implement a 'placebo/falsification' test in which we replace market structure for 
hospitals with the market structure amongst state secondary schools. We reconstruct the 
nlhhi using the shares of secondary school pupils in schools within our GP-centered 
market definition (defined by the 95% referral radius during the pre-policy period). 
Clearly, if choice and competition in the health service drive our results, we would not 
expect to see a significant impact from schooling structure on AMI mortality rates in 
response to the NHS choice reforms. In contrast, if we are simply picking up changes in 
mortality trends in dense versus less dense places then the market structure in schooling 
is just as likely to produce a 'false positive' result. Reassuringly, the coefficient on the 
interaction between post-reform trends and schooling structure is near zero and 
insignificant. 
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To illustrate that our results are the result of changes in hospital quality, rather than the 
result of different patient populations living in high versus low competition regions, we 
estimated (2) using hospital * year fixed effects.  Hospital * year fixed effects should 
capture improvements in quality from hospitals year to year.  When we estimated (2) and 
included hospital * year fixed effects, it washed out the effect of competition. 
 
We have also investigated the validity of our choice of 2006 as the start of our "policy 
on" period in the DiD analysis. As already discussed, there were elements of reform 
before January 2006, but we argued that: a) these reforms were not general enough to 
have made any impact; and b) that the correct incentives were not in place. To 
demonstrate the credibility of our choice of policy-on date, we have re-estimated 
Equation (2) using a three-part time spline interacted with the nlhhi index of market 
concentration. We find here that market structure was not linked to declining AMI 
mortality rates in the 2002-2003 period or the 2004-2005 periods: the coefficients and 
standard errors are respectively 0.05(0.18) and 0.04(0.30). However, the rate of mortality 
decline in high-competition areas increases dramatically for the 2006-2008 period, with a 
coefficient of -0.0059 (0.0032). Although the DiD estimate in the three-way spline is just 
below significance, the point estimates validate our choice of policy-on date. 
 
 
6. Conclusions 
 
Financial incentives are playing an increasingly large role in health care provision and the 
management of health care systems.  In the US, England and the Netherlands, there has 
been significant attention paid to the potential for hospital competition to drive increases 
in quality and efficiency.  However, despite the popularity of patient choice and hospital 
competition as policy tools, there remains considerable uncertainty surrounding how 
health care markets should be optimally structured.  One significant strand of the debate 
about hospital market structure has been whether or not prices should be fixed when 
quality signals are noisy.  Wider economic theory gives a clear response: under a fixed 
regime, competition will improve quality. This will improve consumer welfare, but the 
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effect on social welfare is unclear as quality may be improved past an optimal level. 
Under a variable price regime, the outcome with respect to quality is ambiguous at best. 
Research on the impact of competition on clinical quality during the NHS internal market 
in the 1990s confirms that hospital competition in a market with variable prices may lead 
to higher mortality (Propper et al., 2008, Propper et al., 2004).  More than a decade after 
the internal market, a new government in the UK introduced a further set of market-based 
reforms to the English NHS that relied on hospital competition in a market where prices 
were fixed.  These reforms differed from the internal market in several ways.  First, the 
reforms gave patients a choice of where to receive care and aimed to assist and inform 
decision-making by providing patients with information on hospital quality.  Second, the 
reforms aimed to increase the role of private sector hospitals and increase hospitals’ fiscal 
and managerial autonomy.  Third, the second wave of reforms, unlike the initial internal 
market, had hospitals competing on quality in a market with fixed prices.  To this day, 
these reforms remain controversial and there has been no rigorous assessment of their 
impact on clinical quality. 
This paper offers an empirical assessment of this second wave of reforms and specifically 
analyzes the impact of hospital competition from 2006 onwards on clinical performance, 
as indicated by 30-day AMI mortality.  In this study, we rely on patient level micro data 
and take advantage of the fact that the government’s 2006 market-based reforms would 
have significantly more ‘bite’ in geographic regions where patient choice and hospital 
competition were possible.  We use a modified DiD estimator to examine whether, 
controlling for patient and hospital characteristics, higher competition was associated 
with lower AMI mortality.  We were also conscious that there is significant debate about 
how to empirically measure hospital competition.  As a result, rather than relying on one 
single measure of competition or lone market definition, we use four different types of 
market definitions and two measures of competition to estimate the degree of hospital 
competition in England. 
In our analysis, we consistently find that higher competition was associated with a faster 
decrease in 30-day AMI mortality after the formal introduction of patient choice in 
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January 2006.  We find that one standard deviation increase in competition was 
associated with an approximately 1% additional reduction in AMI mortality in the 3-year 
post policy period that we studied.  Our results are robust to a number of specifications. 
Our results are also robust regardless of how we estimate competition. 
The title of our paper asked whether or not hospital competition saved lives in the 
English NHS.  Our results suggest that they did.  Consistent with previous work from 
Kessler and McClellan (2000) and Kessler and Geppert (2005), we find that hospital 
competition in markets with fixed prices leads to a reduction in AMI mortality.  Our 
results add support to current efforts in England to increase the amount of publicly 
available information on quality and promote hospital competition.  Further, our results 
likely highlight the importance of agents in health care markets. Patients seldom need the 
same surgical or clinical procedure twice, so they are rarely able to take advantage of the 
information they acquire on provider quality ex post.  However, in England, where GPs 
serve as agents for multiple patients with the same condition and play an active roll 
advising patients on where to go for care, it is likely that incentives for quality were 
sharper because GPs could take advantage of their knowledge of previous patients’ 
clinical outcomes to inform their advice to future patients. 
The conclusion, then, is that hospital competition, under the recent NHS reforms, which 
introduced a fixed priced market, did lead to an increase in the quality of hospital 
services, as economic theory would predict.  This rise in quality has undoubtedly led to 
an increase in consumer welfare.  We postulate that, given the level of quality 
improvements that can be attributed to these reforms and the assumed quality levels prior 
to the reforms, these results are consistent with an overall improvement in social welfare 
(McClellan et al., 1999).  However, more research needs to be carried out to prove that 
assertion empirically. 
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Table 1. Correlations Between Different Measures of Competition 
 -log(HHI) -
75% 
-log(HHI)- 
95% 
-log(HHI)- 
30Km 
-log(HHI)- 30 
Minutes 
Mean S.D.
-log(HHI)-
75% 
1.00    0.36 0.40
-log(HHI)- 
95% 
0.71 1.00   0.75 0.56
-log(HHI)- 
30Km 
0.36 0.43 1.00  1.27 0.81
-log(HHI)- 30 
Minutes 
0.41 0.48 0.92 1.0 1.49 0.91
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Table 2. Average 30-day AMI mortality and average nlhhi within a market defined as the 
95th percentile of each GP’s maximum travel distance per year. 
Year Average 30-day AMI Mortality nlhhi 
2002 0.154 0.725 
2003 0.148 0.737 
2004 0.139 0.747 
2005 0.136 0.735 
2006 0.128 0.782 
2007 0.122 0.835 
2008 0.117 0.874 
Overall 0.135 0.774 
Sample restricted to patients between 40 and 100 years of age; hospitals which treat more 
than 25 AMIs per year, and patients who had a length of stay greater than 2 days or who 
died within the first two days. 
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Table 3: Least squared estimates of (2).  Competition measured as the negative ln of the 
HHI within a market that captures all hospitals within the 95th percentile of each GP’s 
maximum travel distance. 
 (1) (2) (3) (4) (5) 
2002 – 2005 Trend -0.0071***
(0.0008)
-0.0102***
(0.0008)
-0.0101***
(0.0008)
-0.0094*** 
(0.0000) 
-0.0096*
(0.0008)
2006 – 2008 Trend 0.0059**
(0.0021)
0.0051*
(0.0021)
0.0053*
(0.0021)
0.0040 
(0.0022) 
0.0043
(0.0022)
2002 – 2005 Trend 
* nlhhi 
0.0016*
(0.0008)
0.0007
(0.0008)
0.0012
(0.0008)
0.0004 
(0.0008) 
0.0006
(0.0008)
2006 – 2008 Trend 
* nlhhi 
-0.0065**
(0.0023)
-0.0057*
(0.0022)
-0.0068*
(0.0022)
-0.0050* 
(0.0023) 
-0.0056*
(0.0023)
Nlhhi -0.0027
(0.0028)
0.0027
(0.0027)
-0.0006
(0.0029)
-0.0008 
(0.0032) 
-0.0013
(0.0033)
      
Patient 
Characteristics 
No Yes Yes Yes Yes 
Hospital Fixed 
Effects 
No No Yes No Yes 
GP Fixed Effects No No No Yes Yes 
      
N 407,882 407,882 407,882 407,882 407,882 
R2 0.037 0.110 0.110 0.093 0.126 
      
Dependent Variable = 1 if patient died within 30-days of their admission to hospital  
 
Hospital characteristics: Hospital type (foundation trust, teaching hospital or traditional 
acute hospital), number of AMIs treated at the hospital per year.  Patient characteristics: 
age, gender, Charlson comorbidity score. Patient socioeconomic status measured using 
the income component of the 2004 Index of Multiple Deprivations at the output area.   
 
Error terms are clustered around GP-practices.  
 
* Significant at 5% level; ** Significant at 1% ,*** Significant at 0.1% 
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Table 4.  Least squared estimates of  (2) using five different measures of competition:  (1) = 
negative ln of HHI within 95% variable radius market; (2) = negative ln of HHI within 75% 
variable radius; (3) = negative ln of HHI within fixed 30km radius market; (4) = negative ln of HHI 
within  market defined by 30-minute drive time from each GP practice; (5) ln of HHI within 95% 
variable market with competition measured as the average HHI between 2002 and 2005 prior to the 
reforms.   
 (1) (2) (3)  (4) (5) (6) 
2002 – 2005 
Trend 
-0.0096* 
(0.0008) 
-0.0098***
(0.0008)
-0.0105***
(0.0009)
-0.0102***
(0.0008)
-0.0099*** 
(0.0008) 
-0.0120*** 
(0.0027) 
2006 – 2008 
Trend 
0.0042 
(0.0022) 
0.0026
(0.0022)
0.0055*
(0.0023)
0.0044
(0.0021)
0.0028 
(0.0020) 
0.0143* 
(0.0061) 
2002 – 2005 
Trend * nlhhi 
0.0006 
(0.0008) 
0.0010
(0.0014)
0.0011*
(0.0005)
0.0011*
(0.0005)
0.0011 
(0.0009) 
0.0038 
(0.0034) 
2006 – 2008 
Trend * nlhhi 
-0.0056* 
(0.0023) 
-0.0081*
(0.0038)
-0.0042**
(0.0013)
-0.0041**
(0.0015)
-0.0048* 
(0.0024) 
-0.0183* 
(0.0081) 
nlhhi -0.0013 
(0.0032) 
-0.0014
(0.0051)
0.0022
(0.0069)
0.0017
(0.0066) - 
-0.0109 
(0.0168) 
       
Patient 
Characteristics 
Yes Yes Yes Yes Yes Yes 
Hospital Fixed 
Effects 
Yes Yes Yes Yes Yes Yes 
GP Fixed 
Effects 
Yes Yes Yes Yes Yes Yes 
       
N 407,882 301,957 445,041 442,844 407,882 377,218 
R2 0.126 0.132 0.126 0.126 0.126 0.128 
       
Dependent Variable = 1 if patient died within 30-days of their admission to hospital  
 
Hospital characteristics: Hospital type (foundation trust, teaching hospital or traditional acute 
hospital), number of AMIs treated at the hospital per year.  Patient characteristics: age, gender, 
Charlson comorbidity score. Patient socioeconomic status measured using the income component 
of the 2004 Index of Multiple Deprivations at the output area.   
 
Error terms are clustered around GP-practices.  
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Table 5.  Least squared estimates of (2) with competition measured as the count of 
hospitals within 4 market definitions: (1) 95% variable market; (2) 75% Variable market; 
(3) Fixed 30km radius market; (4) market defined 30-minute travel time from each GP 
 (1) (2) (3) (4) 
2002 – 2005 
Trend 
-0.0096***
(0.0007)
-0.0095***
(0.0007)
-0.010*** 
(0.0007) 
-0.0098***
(0.0007)
2006 – 2008 
Trend 
0.0031
(0.0017)
0.0055**
(0.0019)
0.0028 
(0.0016) 
0.0031
(0.0019)
2002 – 2005 
Trend * nlhhi 
0.0001
(0.0001)
0.0002
(0.0002)
0.0001 
(0.0001) 
0.0002
(0.0001)
2006 – 2008 
Trend * nlhhi 
-0.0006*
(0.0003)
-0.0024***
(0.0006)
-0.0004** 
(0.0001) 
-0.0006**
(0.00020
Nlhhi -0.0005
(0.0004)
-0.0006
(0.0007)
0.0001 
(0.0008) 
0.0002
(0.0004)
     
Patient 
Characteristics 
Yes Yes Yes Yes 
Hospital Fixed 
Effects 
Yes Yes Yes Yes 
GP Fixed 
Effects 
Yes Yes Yes Yes 
     
N 407,882 407,882 445,041 442,844 
R2 0.126 0.0126 0.126 0.126 
     
Dependent Variable = 1 if patient died within 30-days of their admission to hospital  
 
Hospital characteristics: Hospital type (foundation trust, teaching hospital or traditional 
acute hospital), number of AMIs treated at the hospital per year.  Patient characteristics: 
age, gender, Charlson comorbidity score. Patient socioeconomic status measured using 
the income component of the 2004 Index of Multiple Deprivations at the output area.   
 
Error terms are clustered around GP-practices.  
 
* Significant at 5% level; ** Significant at 1% ,*** Significant at 0.1%at 1% ,*** 
Significant at 0.1% 
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Table 6.  Robustness Tests 
 Instrumented Measure of 
Competition 
Falsification Test 
2002 – 2005 Trend -0.0119*** 
(0.0015) 
-0.0112*** 
(0.0013) 
2006 – 2008 Trend 0.0088* 
(0.0044) 
0.0020 
(0.0035) 
2002 – 2005 Trend * nlhhi 0.0038 
(0.0020) 
0.00056 
(0.0005) 
2006 – 2008 Trend * nlhhi -0.0118* 
(0.0058) 
-0.0007 
(0.0009) 
nlhhi -0.0188* 
(0.0072) 
- 
   
Patient Characteristics Yes Yes 
Hospital Fixed Effects Yes Yes 
GP Fixed Effects Yes Yes 
   
N 425,376 420, 075 
R2 0.109 0.125 
   
Dependent Variable = 1 if patient died within 30-days of their admission to hospital  
 
Hospital characteristics: Hospital type (foundation trust, teaching hospital or traditional 
acute hospital), number of AMIs treated at the hospital per year.  Patient characteristics: 
age, gender, Charlson comorbidity score. Patient socioeconomic status measured using 
the income component of the 2004 Index of Multiple Deprivations at the output area.   
 
Error terms are clustered around GP-practices.  
 
* Significant at 5% level; ** Significant at 1% ,*** Significant at 0.1%at 1% ,*** 
Significant at 0.1% 
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Figure 1.  Timeline for the second wave of NHS market-based reforms - 2001 - 2008 
 
 
2001 2002 2003 2004 2005 2006 20082007
Choice 
pilots begin 
for heart 
disease and 
elective 
patients in 
London
April 2004: 
“Payment by 
Results” for 
20 
Foundation 
Trusts
Jan 2006: All 
patients can 
choose f rom 
4-5 
providers. 
“Choose and 
Book” 
system for 
online 
bookings.
NHS Choice 
website 
goes online.  
Website has 
provider 
quality 
information
Patients can 
choose to 
attend any 
provider in 
England for 
care
Consistent increases in NHS-wide funding
Private sector hospitals increasingly enter the market to of fer elective care to NHS patients
Patients 
waiting > 6 
months can 
choose 
provider with 
shorter wait
April 2005: 
“Payment by 
Results” for 
all NHS 
providers
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Figure 2a: Geographical distribution of health market competition index 
2008, based on hospital sites within 30 minute drive time from GP 
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Figure 2b: Geographical distribution of health market competition index 2008, 
based on hospital sites within 95th percentile GP referral radius 
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Appendix 1 – Least squared estimates of (2) 
Appendix 1: Least squared estimates of (2) with competition measured as the negative ln 
of the HHI within a market that captures all hospitals within the 95th percentile of each 
GP’s maximum travel distance. 
 Coef Standard Error 
2002 – 2005 Trend -0.0096* 0.0008
2006 – 2008 Trend 0.0043 0.0022
2002 – 2005 Trend * nlhhi 0.0006 0.0008
2006 – 2008 Trend * nlhhi -0.0056* 0.0023
Nlhhi -0.0013 0.0033
 
Female 0.0123*** 0.0012 
Charlson2 0.0355*** 0.0013 
Charlson3 0.0774*** 0.0021 
Charlson4 0.1218*** 0.0034 
Charlson5 0.1412*** 0.0056 
Charlson6 0.1925*** 0.0072 
IMD Income 2 0.0005 0.0019 
IMD Income 3 0.0047* 0.0019 
IMD Income 4 0.0044* 0.0019 
IMD Income 5 0.0056** 0.0021 
age4549 -0.0024 0.0022 
age5054 0.0054* 0.0021 
age5559 0.0123*** 0.0021 
age6064 0.0263*** 0.0022 
age6569 0.0453*** 0.0022 
age7075 0.0742*** 0.0023 
age7579 0.1163*** 0.0024 
age8084 0.1544*** 0.0025 
age8589 0.1971*** 0.0028 
Age90plus 0.2573*** 0.0035 
Teaching -0.0035 0.0123 
FT 0.0049 0.0022 
Site Activity (150-300) -0.0079* 0.0036 
Site Activity (300-450) -0.0202*** 0.0038 
Site Activity (450+) -0.0276*** 0.0041 
Distance 0.0000*** 0.0000 
February -0.0041 0.0026 
March -0.0087** 0.0025 
April -0.0082** 0.0025 
May -0.0119*** 0.0025 
June -0.0146*** 0.0026 
July -0.0159*** 0.0026 
August -0.0148*** 0.0026 
September -0.0161*** 0.0026 
October -0.0143*** 0.0025 
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November -0.0116*** 0.0026 
December -0.0096*** 0.0025 
North East * Year -0.0003** 0.0001 
Yorkshire and Humbler * Year -0.0001 0.0001 
North West * Year 0.0001** 0.0000 
East Midlands * Year 0.0000 0.0000 
West Midlands * Year 0.0000 0.0000 
East of England * Year 0.0000 0.0001 
South East Coast * Year 0.0000 0.0000 
South Central * Year -0.0001 0.0001 
South West * Year 0.0000 0.0000 
 
N 407,882 
R2 0.126 
Dependent Variable = 1 if patient died within 30-days of their admission to hospital  
 
Hospital characteristics: Hospital type (foundation trust, teaching hospital or traditional 
acute hospital), number of AMIs treated at the hospital per year.  Patient characteristics: 
age, gender, Charlson comorbidity score. Patient socioeconomic status measured using 
the income component of the 2004 Index of Multiple Deprivations at the output area.   
 
Error terms are clustered around GP-practices.  
Reference categories: Male, Charlson1, IMD-Income1, Age 40-44, Traditional NHS 
Trust, Site Activity (0-150), January, London SHA.   
 
* Significant at 5% level; ** Significant at 1% ,*** Significant at 0.1% 
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